Intas Pharmaceuticals Sues Arinna Lifesciences for Trademark Violation

AHMEDABAD, India, October 29, 2014 /PRNewswire/ --

Intas Pharmaceuticals, leading pharmaceutical company, has approached Delhi High Court citing trademark violation by a recently launched enterprise, Arinna Lifesciences, and has got an ex parte injunction against the sale of anti-epilepsy drug Valrope. According to Intas' case, Valrope is confusingly similar to Intas' well-established brand 'Valprol', which is in the market since 1991.

The court by its order has restrained Arinna lifesciences "through their principal officers, directors, agents, servants, dealers, distributors or anyone for and on their behalf from using, advertising, marketing, selling or using on the internet or as a domain name or in any manner whatsoever the trademark/name Valrope or any other mark/name which is identical and deceptively similar to Intas' trademark Valprol till further orders."

The court has observed that since Vivek Seth, the director of Arinna Lifesciences was "the former employee of Intas holding senior position of Vice President at Intas, and heading the CNS division and having control over the sales and sales representatives of Intas, the chances of confusion between Intas' Valprol and the recently launched Valrope are high."

The court has also passed this order stating that Intas "has been able to make prima facie case for protection of its trademark and if injunction is not granted, the organization will suffer irreparable loss and injury."

About Intas Pharmaceuticals

Intas is a research-based vertically integrated pharmaceutical company predominantly engaged in the business of manufacturing and marketing of pharmaceutical products and medicinal preparations for human and animal care. The annual turnover of Intas for the financial year 2013-2014 was approximately USD 750 million.

Intas is a leading multi-specialty pharmaceutical organisation committed to deliver affordable and innovative pharmaceutical solutions. The company is now the 12th largest pharmaceutical company in the domestic market (as per IMS Health India, Secondary Stockist Audit (SSA), April 2014 MAT). Intas is one of the leading players in chronic therapy in the domestic market. Its portfolio extends to central nervous system (CNS, cardiovascular system (CVS), oncology, diabetes, gastroenterology, pain management, urology, nephrology, gynecology, infertility and respiratory care. Intas has a presence in more than 70 countries worldwide with a robust sales, marketing and distribution infrastructure in highly regulated markets like North America, Europe, South Africa, Australia and New Zealand among others.

For more information, visit www.intaspharma.com

Media Contact: Gaurang Darji, [email protected], +91-9925038960, General Manager - Corporate Affairs, One Advertising & Communication Services Ltd.